


REVIEW



Primary immunodeficiency diseases of adults: a review of pulmonary complication imaging findings

Philippe A. Grenier^{1*} , Anne Laure Brun², Elisabeth Longchamp³, Madeleine Lipski², François Mellot² and Emilie Catherinot^{4,5}

Abstract Our objective in this review is to familiarize radiologists with the spectrum of initial and progressive CT manifestations of pulmonary complications observed in adult patients with primary immunodeficiency diseases, including primary antibody deficiency (PAD), hyper-IgE syndrome (HIES), and chronic granulomatous disease (CGD). In patients with PAD, recurrent pulmonary infections may lead to airway remodeling with bronchial wall-thickening, bronchiectasis, mucus-plugging, mosaic perfusion, and expiratory air-trapping. Interstitial lung disease associates pulmonary lymphoid hyperplasia, granulomatous inflammation, and organizing pneumonia and is called granulomatous-lymphocytic interstitial lung disease (GLILD). The CT features of GLILD are solid and semi-solid pulmonary nodules and areas of air space consolidation, reticular opacities, and lymphadenopathy. These features may overlap those of mucosa-associated lymphoid tissue (MALT) lymphoma, justifying biopsies. In patients with HIES, particularly the autosomal dominant type (Job syndrome), recurrent pyogenic infections lead to permanent lung damage. Secondary infections with aspergillus species develop in pre-existing pneumatocele and bronchiectasis areas, leading to chronic airway infection. The complete spectrum of CT pulmonary aspergillosis may be seen including aspergillomas, chronic cavitary pulmonary aspergillosis, allergic bronchopulmonary aspergillosis (ABPA)-like pattern, mixed pattern, and invasive. Patients with CGD present with recurrent bacterial and fungal infections leading to parenchymal scarring, traction bronchiectasis, cicatricial emphysema, airway remodeling, and mosaicism. Invasive aspergillosis, the major cause of mortality, manifests as single or multiple nodules, areas of airspace consolidation that may be complicated by abscess, empyema, or contiguous extension to the pleura or chest wall.

Clinical relevance statement Awareness of the imaging findings spectrum of pulmonary complications that can occur in adult patients with primary immunodeficiency diseases is important to minimize diagnostic delay and improve patient outcomes.

Key Points • *Unexplained bronchiectasis, associated or not with CT findings of obliterative bronchiolitis, should evoke a potential diagnosis of primary autoantibody deficiency.*

• *The CT evidence of various patterns of aspergillosis developed in severe bronchiectasis or pneumatocele in a young adult characterizes the pulmonary complications of hyper-IgE syndrome.*

*Correspondence:

Philippe A. Grenier
psl.agenda.pg@gmail.com

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

• *In patients with chronic granulomatous disease, invasive aspergillosis is relatively frequent, often asymptomatic, and sometimes mimicking or associated with non-infectious inflammatory pulmonary lesions.*

Keywords Bronchiectasis, Interstitial lung disease, Pulmonary lymphoma, Pulmonary infection

Introduction

Primary immunodeficiency diseases are a heterogeneous group of inborn errors of immunity exceeding 400 distinct disorders, listed by the International Union of Immunological Societies, mainly defined by specific underlying gene defects [1]. The median age of the first symptoms is 2 years, but 25% of patients develop symptoms after 15 years [2]. Among primary immunodeficiency diseases, primary antibody deficiencies (PADs) are the most common group that have better long-term prognoses and are often diagnosed in adulthood [2, 3]. Furthermore, meticulous medical care and broad-spectrum antimicrobial prophylaxis have enabled patients with other primary immunodeficiency diseases, like those with hyper-IgE syndrome (HIES) or chronic granulomatous disease (CGD) to live to early-to-mid adulthood [4].

Pulmonary complications occurring in patients with primary immunodeficiency disease include infection-related, immune-mediated, and neoplastic diseases. Recurrent acute-onset respiratory tract infections may have long-term effects on the lung architecture, inducing airway remodelling (small airway obstruction and bronchiectasis). The immune dysregulation, characteristic of these diseases can affect multiple organs, including the lungs with non-infectious inflammatory pulmonary infiltration [5]. Finally, some of these diseases are associated with an increased risk of lymphoma, which is a major cause of morbidity and mortality [2, 6].

Computed tomography (CT) has become essential for diagnosing bronchiectasis, small-airway diseases, and non-infectious infiltrative lung disease. CT is also used to monitor disease progression, even if magnetic resonance (MR) imaging offers a radiation-free alternative to CT, particularly for chest surveillance [7]. The aim of this review is to familiarize radiologists with the spectrum of initial and progressive CT manifestations of primary immunodeficiency diseases pulmonary complications, which might achieve earlier diagnosis, thereby potentially improving management. For each of the three entities (PAD, HIES, CGD), we present the imaging features, differential diagnosis, and monitoring of pulmonary complications.

Primary antibody deficiency

Primary antibody deficiencies (PADs) are the most commonly diagnosed inborn error of immunity, consisting of numerous conditions in which impairment of

immunoglobulin production is the predominant pattern. This antibody deficiency may be due to intrinsic B-cell defects, but can also involve functional impairment of other immune cells that promote antibody responses [3]. Tables 1 and 2 summarize the causes, and main clinical, biological, and radiological manifestations of the different disorders considered PADs.

Common variable immunodeficiency (CVID) is the most frequently encountered symptomatic PAD. Its estimated prevalence is between 1:25,000 and 1:50,000 affecting men and women equally [3]. CVID is characterized by defective B-lymphocyte differentiation, hypogammaglobulinemia (low IgG and IgA levels), defective antibody responses, and cellular immune defects [8, 9]. It is associated with immune cytopenias, splenomegaly, lymphoproliferative disorders, and granulomatous infiltration of various organs [10].

Selective IgA deficiency (IgAD) is characterized by a very low or no circulating IgA with normal IgG and IgM, and normal IgG subclasses, specific antibodies, and circulating B cells. It is the overall most common PAD, with a prevalence of ~1:600 individuals in Europe and North America [3]. Approximately two-thirds of IgAD-diagnosed patients are asymptomatic. One-third may suffer from bacterial infections, gastrointestinal disorders, autoimmunity, and atopy. X-linked agammaglobulinemia (XLA) is due to mutations in the Bruton tyrosine kinase gene carried on the X chromosome and is characterized by a profound decrease of circulating B cells and very low IgA, IgG, and IgM. Most XLA patients are diagnosed before the age of 5 years and suffer from recurrent pneumonia, sinusitis, otitis, and conjunctivitis.

Excepted for IgG-subclass deficiency which presents almost the same prevalence as CVID, the other PAD diseases are rare or very rare (Tables 1 and 2).

Respiratory infections and airway remodeling

The principal clinical manifestations of PAD are recurrent bacterial infections of the upper and lower respiratory tract. Chronic bronchitis and recurrent pneumonia are common, especially before starting immunoglobulin replacement therapy (IGRT) [3]. Encapsulated bacteria (*Haemophilus influenzae*, *Streptococcus pneumoniae*) are the most causative agents of recurrent infections and can lead to acute complications including pleurisy, empyema, and bronchospasm, and may be of particular importance to the development of chronic lung disease. Furthermore,

Table 1 Pathophysiology and immune characteristics, clinical manifestations, and main chest radiological abnormalities of main primary antibody deficiencies (PADs) [2, 3]

Entity	Pathophysiology and immune characteristics	Clinical manifestations	Main chest radiological abnormalities
CVID with no gene defect specified	Heterogeneous group of disorders involving both B-cell and T-cell immune function Predominant biologic manifestation is hypogammaglobulinemia in individuals aged ≥ 4 years old Normal or decreased number of circulating B cells Low IgG, low IgA and/or IgM Defective antibody responses	Recurrent bacterial infections of the upper and lower respiratory tract Two thirds of patients present noninfectious manifestations including auto-immunity, lymphoproliferative disorders and/or granulomatous infiltration of organs At least 10–20% of CVID patients have ILD Cancer, a major cause of patient deaths, particularly lymphoma and gastric cancers	Airway remodeling: bronchiectasis, bronchial wall thickening, mucoid impactions, atelectasis, mosaic attenuation and expiratory air trapping GLILD: solid and non-solid nodules, areas of consolidation and ground glass opacities often associated with lymphadenopathy. Peri-bronchial and bronchial wall thickening and reticular opacities Pulmonary lymphoma: lymphadenopathy and pulmonary nodules and masses in a peri-lymphatic distribution
IgAD	Characterized by a very low or no circulating IgA with normal IgG and IgM, in individuals aged ≥ 4 years old while IgG subclasses, specific antibodies and circulating B cells are normal	Approximately two-thirds of diagnosed patients are asymptomatic. One third may suffer from bacterial infections, gastrointestinal disorders, autoimmunity and atopy	Bronchiectasis, bronchial wall thickening and mucus plugging Occasionally GLILD: solid and non-solid nodules, areas of consolidation and ground glass opacities, and/or reticular opacities sometimes associated with lymphadenopathy
XLA	Mutations in Bruton tyrosine kinase gene carried on the X chromosome Circulating B cells profoundly decreased Very low IgG and IgA and IgM	Most patients diagnosed before the age of 5 years. Recurrent pneumonias, sinusitis, otitis and conjunctivitis	High rate of bronchiectasis, bronchial wall thickening, mucus plugging, and atelectasis
IgG-subclass deficiency and SPAD	Characterized by a lack of at least one IgG subclass, frequently associated with IgA deficiency. Normal or immature B cells. Deficiency of IgG1 usually associated with low IgG (CVID or other hypogammaglobulinemia). IgG3 deficiency is the most common in adults. IgG2 deficiency may be associated with poor responses to polysaccharide antigens. SPAD is defined by poor responses to polysaccharide antigens with normal IgG subclasses and normal response to conjugate vaccines	Usually asymptomatic Those with a poor response to polysaccharide antigens have increased risk of infections with capsulated bacteria (invasive and sinopulmonary infections)	Bronchiectasis, bronchial wall thickening and mosaic attenuation and air trapping. Occasionally GLILD particularly when IgA deficiency is associated

Abbreviations: CVID, common variable immunodeficiency; IgAD, IgA deficiency; GLILD, granulomatous lymphocytic interstitial lung disease; XLA, X-linked agammaglobulinemia; SPAD, specific antibody deficiency

Table 2 Pathophysiology and immune characteristics, clinical manifestations, and main chest radiological abnormalities of other primary antibody deficiencies (PADs): combined immune deficiency and syndromes with autoimmunity [2, 3]

Entity	Pathophysiology and immune characteristics	Clinical manifestations	Main chest radiological abnormalities
Hyper-IgM syndrome	Combined immune deficiency characterized by defective B-cell–isotype class-switching. Low IgG and IgA concentrations, and normal-to-high IgM levels The most common and severe form (70%) is X-linked, and caused by CD40-ligand mutations	Sinopulmonary and gastrointestinal infections and auto-immune diseases Enhanced susceptibility to bacterial pathogens and opportunistic infections like <i>Pneumocystis jirovecii</i>	Bronchiectasis Hilar lymphadenopathy and perihilar opacities
Activated PI3K-delta syndrome	Combined immune deficiency resulting from autosomal dominant gain of function mutation in PI3KCD Low CD4 T cells. Variable hypogammaglobulinemia, hyper IgM, low serum Ig2 in most patients, poor responses to vaccination	Recurrent sinopulmonary bacterial and Herpes virus infections. Auto-immunity Lymphoid hyperplasia Increased risk of lymphoma Neurodevelopmental delay in some patients	Bronchiectasis and airway damage Pulmonary nodules and compressive masses (lymphocytic infiltration)
CTLA-4 haploinsufficiency	Autosomal-dominant immune-dysregulation syndrome with activated T cell compartment Impaired function of T regs, T-cells and B-cells decreased. Variable hypogammaglobulinemia. Regulatory T cells fail to exert their immune regulatory effect, and auto-aggressive immune-cell invasion attacks the lungs	Recurrent infections Lymphocytic organ infiltration, interstitial lung disease. Auto-immune cytopenias	GLILD relatively common; pulmonary solid and non-solid nodules and areas of airspace consolidation
STAT3 gain-of-function mutations	Autosomal dominant gain of function mutation that leads to enhanced STAT3 signaling Increased Th17 cells differentiation. Decreased T regs and impaired function. T-cells and B-cells decreased Variable hypogammaglobulinemia	Multiorgan autoimmunity, infection susceptibility and lymphoproliferative complications Recurrent and severe infections caused by a broad spectrum of pathogens, including opportunistic infections, particularly mycobacterial	Bronchiectasis, bronchial wall thickening, mosaic attenuation and air trapping GLILD: solid and non-solid pulmonary nodules and areas of air space consolidation and/or reticular opacities
LRBA deficiency	Autosomal recessive deficiency that leads to loss of protein expression. LRBA is a cytosolic protein highly expressed in B and T cells and other cellular lineages Low or normal numbers of B cells; Low or normal number of CD4 T cells; T cells dysregulation. Hypogammaglobulinemia	Manifestations typically begin in early childhood with chronic diarrhea (inflammatory bowel disease), auto-immune disorders and organomegaly. Recurrent respiratory infections	Bronchiectasis GLILD: solid and non-solid pulmonary nodules and areas of air space consolidation and/or reticular opacities

Abbreviations: *PI3K-d*, activated phosphoinositide 3-kinase delta; *CTLA-4*, cytotoxic T-lymphocytic associated protein-4; *STAT3*, signal transducer and activation of transcription 3; *LRBA*, li popolysaccharide-responsive and beige-like anchor protein

non-encapsulated strains have also been identified as an important cause of pneumonia and bronchitis in this population. In addition, some patients may develop opportunistic infections due to *Pneumocystis jirovecii* (Figure S1), viruses, tuberculosis (Figure S2), or nontuberculous mycobacteria, typically seen in patients with T-cell deficiencies [5].

Although early intervention with prophylactic antibiotics and/or IGRT can prevent respiratory infections and pulmonary disease morbidity and mortality, chronic lung disease progresses in many PAD patients. Recurrent infections may instigate a chronic inflammatory response inducing airway hyperreactivity (asthma) and remodeling (bronchial wall-thickening and bronchiectasis), and eventually, irreversible obstruction due to small-airway disease (obliterative bronchiolitis) [8]. The most prevalent PAD-associated radiological manifestation is bronchiectasis associated with small airway disease [9–11]. The three morphological bronchiectasis types (cylindrical, varicose, and cystic) reflect increasingly severe bronchial disease and its progression to the more central airway. Bronchiectasis may affect one or more lobes, involving segmental and/or subsegmental bronchi possibly associated with loss of lobe/segment volume (atelectasis) (Fig. 1a, b). Dilated bronchi may contain retained secretions (mucous-plugging, air-fluid levels). Distal mucoid impaction may manifest as parenchymal centrilobular and tree-in-bud nodularity [10]. The other associated findings include bronchial wall-thickening that may precede bronchiectasis onset, areas of lung hypoattenuation, mosaic perfusion pattern (Fig. 1c), and expiratory air-trapping reflecting small-airway obstruction. A multicenter study on the European Chest CT Group cohort included CT data from 232 CVID patients, 28 XLA patients, and 22 patients with other PAD, 80% of patients had radiological evidence of some form of bronchial pathology including bronchiectasis (61%), bronchial wall-thickening (44%), atelectasis (32%) and/or mucus-plugging (29%) [12]. The prevalence of bronchiectasis and mucus plugging, but not of bronchial wall thickening, were higher in the XLA cohort as compared to the CVID cohort (Fig S3). Patients with less severe forms of PAD, such as IgG subclass deficiency, IgAD, and specific antibody deficiency, may also have an increased risk of bronchiectasis (Fig S4) [9].

Although the course of PAD-related bronchiectasis was shown to be similar to bronchiectasis of other causes [13], non-tuberculous mycobacteria or *Pseudomonas aeruginosa* airway colonization can further worsen lung disease in PAD patients with bronchiectasis [3].

Interstitial lung disease

PAD-related interstitial lung diseases (ILDs) represent a group of diseases relying on a chronic inflammatory and often pro-fibrotic process whose onset is often insidious. An ILD prevalence of at least 10–20% has been reported in CVID, but it is likely underestimated [3]. Occasionally, ILDs may be found in IgAD, particularly when associated with IgG subclass deficiency and with a clinical presentation dominated by autoimmune phenotype [3]. ILD is commonly observed in patients with CTL-4 haploinsufficiency or STAT3 gain-of-function mutations. On the other hand, there is no evidence of ILDs in different cohorts of HIM syndrome and XLA. In terms of severity, there is no data showing specific associations between ILD severity and the type of PAD.

ILD in PAD patients can be considered a pulmonary manifestation of systemic immune dysregulation, representing a serious threat to affected patients' health. It tends to become symptomatic in later stages and chest CT modifications may foresee clinical and functional manifestations. PAD patients' ILD characteristics are typically consistent with one or more forms of benign pulmonary lymphoproliferation, frequently associated with granulomatous inflammation and organizing pneumonia. This association led to the umbrella term: granulomatous-lymphocytic interstitial lung disease (GLILD) (Figs. 2 and 3) [14]. GLILD histopathological abnormalities vary and overlap extensively [15] (Fig. 3c–f). Different pulmonary lymphoid-hyperplasia patterns, including follicular bronchiolitis, lymphocytic interstitial pneumonia, lymphocytic infiltrates, and nodular lymphoid hyperplasia, often occur together and are rarely found alone [15] (Fig. 3c–d). The granulomata (Fig. 3f) can vary from poorly-to-well circumscribed, sharing some histological features with sarcoidosis and hypersensitivity pneumonitis. Organizing pneumonia (Fig. 3e) has been reported in many histological specimens [16]. Although a subgroup of patients had interstitial fibrosis with architectural remodeling, only a few had extensive pulmonary fibrosis as the predominant biopsy finding [17].

GLILD diagnosis is based on a combination of radiological and histopathological findings. Typical CT features include large and small solid or semi-solid nodules, areas of consolidation, and ground-glass opacities (GGOs), mainly located in the lower lung zones and having a predominant peri-broncho-vascular and/or subpleural distribution. These lung abnormalities are frequently associated with hilar and/or mediastinal lymphadenopathy [10, 11, 18] (Fig. 2). Thickening of interlobular septa, peri-bronchial and bronchial wall-thickening, reticular opacities, and bronchiectasis may also be seen (Figs. 2 and 3a, b). Lung fibrosis, when present, manifests as lung




Fig. 1 Unenhanced CT scan in a 35-year-old patient with common variable immunodeficiency (CVID), axial (**a, b**) and coronal oblique with mIP reconstruction (**c**) images. Diffuse bronchial wall thickening, varicose and cylindrical bronchiectasis with lower and right predominance. The mIP reconstruction shows mosaicism, a few scattered cysts in the lung bases and distal traction bronchiectasis in the left lower lobe

architecture distortion, traction bronchiectasis, and focal areas of honeycombing. Based on chest CT findings of 51 serial CVID patients, Maglione et al found ≥ 5 pulmonary nodules, bronchiectasis, and GGOs in 34 (67%), 22 (43%), and 18 (37%) patients, respectively [9].

Histopathological confirmation of the diagnosis of GLILD is recommended. Biopsy of the lung tends to be avoided when the radiological findings are highly suggestive or replaced by a liver or lymph node biopsy. 2-[^{18}F]-Fluoro-2-deoxy-D-glucose positron-emission tomography combined with CT can visualize active lymphoproliferative sites early during the inflammatory process, showing their systemic distribution [19], potentially identifying those to be more suitable for biopsy than the lung and confirming granulomatous inflammation (Figure S5) [5]. However, in some PAD patients presenting CT features of GLILD, a CT-guided lung biopsy may be necessary to differentiate pulmonary nodules or focal air-space consolidation from malignancies, particularly primary lymphoid lesions.

Neoplastic diseases involving the lung

Lymphoma is one of the major causes of death in PAD [20]. Primary lymphoid lesions (low-grade B-cell lymphoma, MALT, or Hodgkin diseases) may affect the

lungs of these patients. On CT, pulmonary lymphoma is characterized by mediastinal, hilar, and axillary lymphadenopathy with pulmonary nodules and masses in a peri-lymphatic distribution (Figure S6) [11]. These lung opacities may become confluent and contain air bronchograms.

Neoplastic lymphoproliferative diseases, especially mucosa-associated lymphoid tissue (MALT) disease must be considered in the differential diagnosis of GLILD [21]. CT-scan analysis of MALT patients found multi-pattern abnormalities in most, predominantly pulmonary nodules and masses containing air bronchograms of dilated or non-dilated airways [20]. Micronodules, GGOs, and septal lines are less frequent in MALT than in GLILD. MALT diagnosis is easily confirmed by bronchial, transbronchial, CT-guided percutaneous, or surgical lung biopsy (Figure S7) [22].

Lung carcinoma has also been reported in CVID patients, but pulmonary metastases from other cancers appear to be more common than primary lung tumors [23].

Lung disease monitoring

Even for those without respiratory symptoms, chest CT and pulmonary function tests (PFT) are recommended




Fig. 2 A middle aged woman with CVID. Post contrast thoraco-abdominal CT scan, axial parenchymal (a, b) and coronal soft tissue (c) images. Lower zone predominant bronchocentric nodules and airspace consolidation consistent with granulomatous-lymphocytic interstitial lung disease (GLILD). The patient also presented with splenomegaly, mediastinal and retroperitoneal lymphadenopathy (arrows)

at PAD diagnosis to look for evidence of chronic lung disease [24]. Then, the next challenge for clinicians and radiologists is the surveillance of these patients. Lung nodule monitoring is entirely relevant, given the heightened malignancy risk of some patients, especially those with CVID. Pertinently, because many of those nodules are benign and wax and wane over time, repeated biopsies might not be necessary. Thus, in the absence of recommended follow-up guidelines, low-dose CT is generally preferred, based on clinical findings with the potential risk of delayed diagnosis for asymptomatic or pauci-symptomatic patients [5]. Contrast is usually not necessary apart from specific indications (haemoptysis, pre-biopsy lymph node assessment, cardiovascular evaluation, suspicion of malignancy). Expiration acquisition is not systematic. Detection of mosaicism and obliterative bronchiolitis can be done by applying the minimum intensity projection technique on a soft kernel window volume and accentuating the contrast (Fig. 1c). Alternatively, MRI provides repeated chest surveillance without radiation exposure and may be useful for clinicians wanting more frequent monitoring (Fig S8) [7]. Actually, one of the main concerns of imaging PAD patients remains the balance between the risks of ionizing radiation and missing bronchiectasis or ILD diagnosis. This is particularly true for CVID patients, who may be more

radiosensitive than healthy subjects, as demonstrated after in vitro chromosomal irradiation [25, 26]. Indeed, enhanced radiosensitivity might explain the higher malignancy rate of these patients.

MRI has proved in patients with CVID or IgAD to give similar results as CT for detecting the presence and extent of consolidation, bullae, mucus plugging, bronchial wall thickening, bronchiectasis severity, and nodules [7, 27, 28]. However, CT better identified peripheral airway abnormalities, and MRI performance was weaker at detecting bronchiectasis extension, with a low concordance between MRI and CT in the assessment of the number of bronchial generations. Today, novel MR sequences using so-called ultrashort (UTE) or zero (ZTE) echo-time techniques can provide image quality similar to that of low-dose CT, at a millimeter to submillimeter spatial resolution. Hence, three-dimensional (3D)-UTE MRI allows in vivo assessment of the severity of structural alterations, with the possibility to apply CT imaging scoring systems at a segmental level of precision [29]. Novel respiratory synchronization systems allow for removing motion artifacts, standardizing the lung volume of acquisition without needing an external device, or repeating breath-hold maneuvers. Furthermore, a promising development of functional proton MRI via Fourier decomposition allows the generation of ventilation- and




Fig. 3 66-year-old male with CVID and biopsy proven GLILD. CT scan (**a, b**) and histological (**c–f**) correlation. **a, b** Smooth and irregular thickening of interlobular septa associated with intralobular reticular lines and architectural distortion in the lower lobes. **c**: diffuse cellular interstitial infiltrate. The alveolar interstitium is markedly expanded by a dense collection of mature lymphocytes and plasma cells (hematoxylin–eosin, original magnification $\times 5$). **d** Follicular bronchiolitis. Dense airway-centered lymphoid hyperplasia with several small nodular lymphoid aggregates (hematoxylin $\times 5$). **e** Polyps of organizing pneumonia (hematoxylin $\times 10$). **f** Non-necrotizing granulomatous inflammation. Scattered loose aggregates of epithelioid histiocytes often found within interstitial lymphoid background (hematoxylin $\times 20$)

perfusion-weighted maps without any contrast agent. [29]. Evaluation of these new techniques for assessing lung disease in PAD patients is highly expected.

Hyper-IgE syndrome (HIES)

Hyper-IgE syndrome (HIES) is a group of monogenic primary immunodeficiencies associated with high serum IgE, eczema, and recurrent lung and skin infections. Job syndrome or autosomal dominant HIES is the prototype of these disorders (Table 3). It is caused by dominant negative mutations in *STAT3*, responsible for a primary immunodeficiency with elevated IgE levels; hypereosinophilia, memory-B-cell lymphopenia, and a low proportion of IL-17-producing TH17 cells. It also affects the connective tissue, skeletal system, vasculature, and dentition [30]. Ninety percent of patients develop recurrent pyogenic caused by *Staphylococcus aureus*, *Sreptococcus pneumoniae*, and *Haemophilus influenzae* pneumonia, which typically begin in the first several years of life and frequently lead to pulmonary sequelae, such as bronchiectasis and pneumatoceles [11, 30]

Once the lung parenchyma is damaged by pyogenic pneumonia, the list of infecting agents expands to

include *Aspergillus fumigatus*, persistent Gram-negative bacilli, like *Pseudomonas*, and non-tuberculous mycobacteria [30]. Commonly, secondary infections with aspergillus species and/or Gram-negative infections cause clinically significant haemoptysis and/or become increasingly resistant to antimicrobial agents. Most aspergillosis-related infections develop in pre-existing pneumatocele and bronchiectasis areas, leading to chronic airway infection [31] (Fig. 4). The CT pulmonary aspergillosis spectrum described in autosomal dominant HIES include (1) aspergillomas with fungus balls within pre-existing lung cavities (bronchiectasis or pneumatoceles), (2) chronic cavitary pulmonary aspergillosis with cavity thickness, fungus balls and peri-cavitary infiltrates, and (3) allergic bronchopulmonary aspergillosis (ABPA)-like with bronchiectasis and mucoid impactions taking the appearance of toothpaste-shaped/finger-in-glove opacities (Figure S9) [25]. Mixed patterns and episodes of invasive aspergillosis can also occur [32]. The CT evidence of various patterns of aspergillosis developed in severe bronchiectasis or pneumatocele in a young adult should raise the potential diagnosis of autosomal dominant HIES.

Table 3 Pathophysiology and immune characteristics, clinical manifestations, and main chest radiological abnormalities of hyper-IgE syndrome (HIES) and chronic granulomatous disease (CGD)

Entity	Pathophysiology and immune characteristics	Clinical manifestations	Main chest radiological abnormalities
Autosomal dominant HIES Also called Job syndrome [24–28]	First cause of HIES, related to loss of function dominant negative <i>STAT3</i> mutation Low percentages of IL-17-producing Th17 cells Memory-B-cell lymphopenia Hyper IgE Defective antibody responses	Recurrent pyogenic pneumonia leading to pulmonary sequelae (bronchiectasis and pneumatoceles) complicated by chronic infections due to <i>Aspergillus fumigatus</i> , persistent Gram-negative bacilli, like <i>Pseudomonas</i> , and non-tuberculous mycobacteria. Atopy Mucocutaneous candidiasis Distinctive facial features (broad nasal bridge), hyperextensible joints, osteoporosis and bone fractures, scoliosis, retention of primary teeth; aneurysm formation	Bronchiectasis. Pneumatoceles Chronic cavitary pulmonary aspergillosis (cavity with thick walls, fungus balls and peri-cavitary infiltrates). Allergic bronchopulmonary aspergillosis (ABPA)-like appearance with bronchiectasis and mucoid impactions
CGD [29–36]	Genetic defect of one of the sub-unit of nicotinamide adenine dinucleotide phosphate (NADPH+) oxidase. This defect renders phagocytic cells unable to produce the reactive oxygen species crucial to killing ingested microorganisms. The most common form (70%) is X-linked, inheritance can also be autosomal-recessive	Recurrent bacterial and fungal infections, mostly affecting the lungs, the liver and the bones Invasive aspergillosis represents the major cause of mortality Chronic non-infectious events may occur in various organs, including the lung	Random pulmonary nodules mainly in the bilateral lower lobes, often associated with GGOs and focal consolidations and masses; cavities and multiple small abscesses may be seen in the focal consolidations and masses. Reticulations, bronchiectasis and pleural effusion can be present. Lymphadenopathies sometimes necrotic

Abbreviations: HIES, hyper-IgE syndrome; CGD, chronic granulomatous disease; GGO, ground glass opacities

Monitoring lung disease

Prophylactic antimicrobials to prevent pyogenic pneumonia and early recognition and treatment of infection are essential to try and prevent the development of pneumatoceles and bronchiectasis. When chronic fungal infection of pneumatoceles or bronchiectatic airways is present, long-term administration of a mold-active

antifungal seems to minimize the spread of infection and associated bleeding. Because antifungals cannot always effectively treat aspergillomas forming inside pneumatoceles, resection has been performed in some patients. However, less than 50% of these lung surgeries may lead to complications with prolonged bronchopleural fistulae, often persisting for months and causing empyema and




Fig. 4 Chronic aspergillosis in a 32-year-old patient with autosomal dominant hyper IgE syndrome (HIES). Axial (a, b) and coronal mIP (c) CT scan images. Large cavities in the left upper lobe (a, c) with evidence of intra-cavitary aspergillomas. Note the thoracic scoliosis, which is a frequent finding in HIES

sometimes requiring re-intervention [33]. Haemoptysis can be a major cause of morbidity and mortality, likely from abnormal vasculature associated with the chronic infection (Fig S10) [34]; sometimes arterial embolization or surgical resection may be required. Invasive fungal disease typically occurs in the fourth decade of life and only when there are concurrent anatomical lung defects from previous bacterial pneumonias. Despite therapy, mortality from invasive fungal disease is significant. Finally, several successful hematopoietic stem cell transplants (HSCT) in patients with autosomal dominant HIES have been published, prompting increased consideration of this option [30].

Chronic granulomatous disease

Chronic granulomatous disease (CGD) is a rare inherited PID caused by a genetic defect of the nicotinamide adenine dinucleotide phosphate oxidase. The mode of inheritance can be X-linked or of autosomal recessive form (Table 3). This defect renders phagocytic cells unable to produce reactive oxygen species (ROS) which are crucial to killing ingested microorganisms [35]. CGD is estimated to occur in ~1/200,000–250,000 live births in the USA [36]. The disease is characterized by recurrent life-threatening infections and inflammatory manifestations

[36]. The lung is the main affected organ. Pulmonary infections are often severe and invasive aspergillosis represents the major cause of mortality. Chronic non-infectious events may occur in various organs including the lung. Anti-microbial prophylaxis with itraconazole and sulphamethoxazole and improved management of infectious and inflammatory complications have, however, dramatically improved CGD outcomes over the last decades [37]. Patients now easily reach adulthood [38].

Respiratory infections

The various pathogens identified in the case of respiratory infections include bacteria, fungi, and *Mycoplasma* [39]. Furthermore, mycobacterial disease is also relatively common in patients with CGD living in countries in which tuberculosis is endemic, the BCG vaccine is mandatory [40]. At diagnosis, chest CT shows random pulmonary nodules ranging from 1 to 3 cm in diameter and mainly in the bilateral lower lobes often associated with GGOs and focal consolidations and masses [39, 40]. Cavities and multiple small abscesses may be seen in the focal consolidations and masses; some patients also have reticulations, bronchiectasis, and pleural effusion(s) (Fig. 5). Fungal infection features tend to be unusual. Numerous patients have neither fever nor respiratory symptoms




Fig. 5 Chronic granulomatous disease (CGD) revealed by a mixed pattern of aspergillosis in a 41 yo man. Coronal post contrast (a) and axial parenchymal (b, c) CT images. Large partially necrotic consolidation in the left upper lobe. Tubular opacities less dense than airspace consolidation are consistent with plugged dilated airways (arrows). Note the presence of underlying varicose bronchiectasis in the same lobe (circle)

[39]. Microbiological identification, mostly *Aspergillus fumigatus* and *Aspergillus nidulans*, is obtained on bronchoalveolar lavage or lung biopsy analysis. *A. nidulans* is clearly over-represented in CGD, compared with other immunodeficiencies, suggesting host–pathogen interactions and the role of NADPH+oxidase within *Aspergillus* species [41]. Single or multiple, uni- or bilateral pulmonary nodules (<30 mm), with or without a halo sign, might represent the first radiological findings of pulmonary fungal infection in CGD [42]. In the analysis of CT scans of 23 adult CGD patients diagnosed with fungal infections, Salvator et al found airspace consolidation, nodules, reticulation, and GGOs in 20, 12, 10, and 11 patients, respectively (FIG S11); chest wall invasion was detected in six patients, with rib lysis in three, subcutaneous abscesses in two, and subclavian artery compression in one (Figure S12) [39]. Lymphadenopathies can be present, sometimes necrotic [11].

Noninfectious pulmonary events

Non-infectious inflammatory pulmonary manifestations have been reported in 23–28% of CGD patients [39, 43]. They were more frequent in the X-linked inheritance group. Two different CT patterns have been described. The first is made up of circumscribed nodules or airspace consolidation, sometimes arising after a respiratory infection; lung biopsy histology may find granuloma and neutrophilic or eosinophilic micro-abscesses. The

second is made up of variable infiltrative lung patterns including disseminated micronodules and peri-bronchial thickening (sarcoid-like pattern) (Fig. 6) or non-specific interstitial pneumonia with GGOs, reticulations, and septal-thickening [39]. Given that infection and chronic inflammation are clearly linked in CGD, a high percentage of those inflammatory events occur simultaneously with an infection, mainly aspergillosis, frequently making lung biopsy necessary to differentiate them from uncontrolled infection, particularly for circumscribed nodules or airspace consolidation.

Monitoring lung disease

Protocols of continuing intensive surveillance and monitoring of compliance with anti-infective regimens may significantly improve the quality of life and long-term survival in patients with CGD [36]. Infections with *Aspergillus* species have become the major cause of infectious complications and death in patients with CGD. Prophylactic and therapeutic measures are needed to further increase life expectancy and quality for patients with CGD [38].

Pulmonary complications indicate poor prognosis and are frequently responsible for sequelae. CT images of retractile lung scarring have been reported in a series of adult CGD patients. Salvator et al examined nine chest CT scans after treatment completion; all showed radiological scarring with local fibrosis, septal-thickening, bronchiectasis, and paraseptal emphysema [39]. The




Fig. 6 Sarcoid-like infiltrative lung disease following systemic aspergillosis in a 46 yo patient with chronic granulomatous disease (CGD). Axial (a, b) and coronal (c) CT scan images show innumerable small nodules with a peri-lymphatic distribution (peri-broncho-vascular, centrilobular and subpleural) predominant in the upper parts of the lungs, associated with perihilar confluence of nodules, and enlarged hilar and mediastinal lymph nodes. Granulomas were confirmed on transbronchial biopsies

burden of these complications raises the question of respiratory monitoring of CGD patients. Systematic low-dose CT every two years has been recommended [39]. For any new respiratory event, management must be initiated early, including CT scans and invasive diagnostic techniques, even lung biopsy.

Conclusions

With improvements in diagnosis and therapy, an increasing number of patients with primary immunodeficiency diseases now survive into adulthood. Hence, radiologists should familiarize themselves with imaging findings associated with these diseases, to raise the diagnosis of primary immunodeficiency disease when confronted with suggestive features or associations and detect complications in the specific subgroups.

Abbreviations

ABPA	Allergic bronchopulmonary aspergillosis
CGD	Chronic granulomatous disease
CT	Computed tomography
CVID	Common variable immunodeficiency
GGO	Ground-glass opacity
GLILD	Granulomatous lymphocytic interstitial lung disease
HIES	Hyper-IgE syndrome
IgAD	Selective IgA deficiency
IGRT	Immunoglobulin replacement therapy
ILD	Interstitial lung disease
MALT	Mucosa-associated lymphoid tissue
MR	Magnetic resonance
PAD	Primary antibody deficiency
PFT	Pulmonary function tests
XLA	X-linked agammaglobulinemia

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1007/s00330-023-10334-7>.

Below is the link to the electronic supplementary material. Supplementary file1 (PDF 1677 KB)

Funding

The authors state that this work has not received any funding.

Declarations

Guarantor

The scientific guarantor of this publication is Philippe A Grenier.

Conflict of interest

The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

Written informed consent was not required for this study because it is a review article.

Ethical approval

Institutional Review Board approval was not required because it is a review article.

Study subjects or cohorts overlap

No study subjects or cohorts have been previously reported.

Methodology

- performed at one institution

Author details

¹Department of Clinical Research and Innovation, Hôpital Foch, Suresnes, France. ²Department of Radiology, Hôpital Foch, Suresnes, France. ³Department of Pathology, Hôpital Foch, Suresnes, France. ⁴Department of Pneumology, Hôpital Foch, Suresnes, France. ⁵CEDITH (Centre de Référence Des Déficiences Immunitaires Héritées), Hôpital Foch Affiliated to Versailles-Saint Quentin University, 40 Rue Worth, 92150 Suresnes, France.

Received: 13 July 2023 Revised: 11 September 2023

Accepted: 13 September 2023 Published online: 8 November 2023

References

1. Tangye SG, Al-Herz W, Bousfiha A *et al* (2019) Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. *J Clin Immunol* 40:24–64
2. Thalhammer J, Kindle G, Nieters A *et al* (2021) Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. *J Allergy Clin Immunol* 148:1332–1341
3. Schussler E, Beasley MB, Maglione PJ (2016) Lung disease in primary antibody deficiencies. *J Allergy Clin Immunol Pract* 4:1039–1052
4. Gennery AR, Holland SM (2015) Primary immunodeficiencies: not just paediatric diseases. *Eur Respir J* 45:1521–1523
5. Baumann U, Routes JM, Soler-Palacín P, Jolles, (2018) The lung in primary immunodeficiencies: new concepts in infection and inflammation. *Front Immunol* 9:1837. <https://doi.org/10.3389/fimmu.2018.01837>
6. Cinetto F, Scarpa R, Rattazzi M, Agostini C (2018) The broad spectrum of lung diseases in primary antibody deficiencies. *Eur Respir Rev* 27:180019. <https://doi.org/10.1183/16000617.0019-2018>
7. Arslan S, Poyraz N, Ucar R, Yesildag M, Yesildag A, Caliskaner AZ (2016) Magnetic resonance imaging may be a valuable radiation-free technique for lung pathologies in patients with primary immunodeficiency. *J Clin Immunol* 36:66–72
8. Gupta S, Pattanaik D, Krishnaswamy G (2019) Common variable immune deficiency and associated complications. *Chest* 156:579–593
9. Maglione PJ, Overbey JR, Radigan L, Bagiella E, Cunningham-Rundles C (2014) Pulmonary radiologic findings in common variable immunodeficiency: clinical and immunological correlations. *Ann Allergy Asthma Immunol* 113:452–459
10. Bang TJ, Richards JC, Olson AL, Groshong SD, Gelfand EW, Lynch DA (2018) Pulmonary manifestations of common variable immunodeficiency. *J Thorac Imaging* 33:377–383
11. Rodriguez JA, Bang TJ, Restrepo CS, Greene DB, Brown LP, Largas D (2021) Imaging features of primary immunodeficiency disorders. *Radiol Cardiothorac Imaging* 3:e200418. <https://doi.org/10.1148/ryct.2021.200418>
12. Schütz K, Aleksandru D, Grimbacher B *et al* (2019) Imaging of bronchial pathology in antibody deficiency: data from the European chest CT group. *J Clin Immunol* 39:45–54
13. Goussault H, Salvator H, Catherinot E *et al* (2019) Primary immunodeficiency-related bronchiectasis in adults: comparison with bronchiectasis of other etiologies in a French reference center. *Respir Res* 20:275–285
14. Hurst JR, Verma N, Lowe D *et al* (2017) British Lung Foundation/United Kingdom primary immunodeficiency network consensus statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders. *J Allergy Clin Immunol Pract* 5:938–945

15. Larsen BT, Smith ML, Tazelaar HD, Yi ES, Ryu JH, Churg A (2020) GLILD revisited: pulmonary pathology of common variable and selective IgA immunodeficiency. *Am J Surg Pathol* 44:1073–1081
16. Dhalla F, Lochlainn DJM, Chapel H, Patel SY (2020) Histology of interstitial lung disease in common variable immune deficiency. *Front Immunol* 11:605187. <https://doi.org/10.3389/fimmu.2020.605187>
17. Ho HE, Cunningham-Rundles C (2020) Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis. *Front Immunol* 11:149. <https://doi.org/10.3389/fimmu.2020.00149>
18. Lopes JP, Ho HE, Cunningham-Rundles C (2021) Interstitial lung disease in common variable immunodeficiency. *Front Immunol* 12:605945. <https://doi.org/10.3389/fimmu.2021.605945>
19. Jolles S, Carne E, Brouns M et al (2017) FDG PET–CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). *Clin Exp Immunol* 187:138–145
20. Quinti I, Agostini C, Tabolli S et al (2012) Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency. *Blood* 30:1953–1954
21. Reichenberger F, Wyser C, Gonon M, Cathomas G, Tamm M (2001) Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome. *Respiration* 68(1):109–112
22. Borie R, Wislez M, Thabut G et al (2009) Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. *Eur Respir J* 34:1408–1416
23. Pulvirenti F, Pecoraro A, Cinetto F et al (2018) Gastric cancer is the leading cause of death in Italian adult patients with common variable immunodeficiency. *Front Immunol* 9:2546. <https://doi.org/10.3389/fimmu.2018.02546>
24. Jolles S, Sánchez-Ramón S, Quinti I et al (2017) Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. *Clin Exp Immunol* 190:226–234
25. Palanduz S, Palanduz A, Yalcin I et al (1998) In vitro chromosomal radiosensitivity in common variable immune deficiency. *Clin Immunol Immunopathol* 86:180–182
26. Mahmoodi M, Abolhassani H, Mozdarani H et al (2018) In vitro chromosomal radiosensitivity in patients with common variable immunodeficiency. *Cent Eur J Immunol* 43:155–161
27. Milito C, Pulvirenti F, Serra G et al (2015) Lung magnetic resonance imaging with diffusion weighted imaging provides regional structural as well as functional information without radiation exposure in primary antibody deficiencies. *J Clin Immunol* 35:491–500
28. Serra G, Milito C, Mitrevski M et al (2011) Lung MRI as a possible alternative to CT scan for patients with primary immune deficiencies and increased radiosensitivity. *Chest* 140:1581–1589
29. Dournes G, Walkup LL, Benlala I et al (2021) The clinical use of lung MRI in cystic fibrosis: what, now, how? *Chest* 159:2205–2217. <https://doi.org/10.1016/j.chest.2020.12.008>
30. Freeman AF, Olivier KN (2016) Hyper-IgE syndromes and the lung. *Clin Chest Med* 37:557–567
31. Duréault A, Tcherakian C, Poiree S et al (2019) Spectrum of pulmonary aspergillosis in hyper-IgE syndrome with autosomal-dominant STAT3 deficiency. *J Allergy Clin Immunol Pract* 7:1986–1995
32. Vinh DC, Sugui JA, Hsu AP, Freeman AF, Holland SM (2010) Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. *J Allergy Clin Immunol* 125:1389–1390
33. Freeman AF, Renner ED, Henderson C et al (2013) Lung parenchyma surgery in autosomal dominant hyper-IgE syndrome. *J Clin Immunol* 33:896–902
34. Freeman AF, Kleiner DE, Nadiminti H et al (2007) Causes of death in hyper-IgE syndrome. *J Allergy Clin Immunol* 119:1234–1240
35. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM (2000) Genetic, biochemical, and clinical features of chronic granulomatous disease. *Medicine (Baltimore)* 79:170–200
36. Martire B, Rondelli R, Soresina A et al (2008) Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. *Clin Immunol* 126:155–164
37. Gallin JI, Alling DW, Malech HL et al (2003) Itraconazole to prevent fungal infections in chronic granulomatous disease. *N Engl J Med* 348:2416–2422
38. Liese J, Kloos S, Jendrossek V et al (2000) Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. *J Pediatr* 137:687–693
39. Salvator H, Mahlaoui N, Catherinot E et al (2015) Pulmonary manifestations in adult patients with chronic granulomatous disease. *Eur Respir J* 45:1613–1623
40. Conti F, Lugo-Reyes SO, Blancas Galicia L et al (2016) Mycobacterial disease in patients with chronic granulomatous disease: a retrospective analysis of 71 cases. *J Allergy Clin Immunol* 138:241–248
41. Henriot SS, Verweij PE, Warris A (2012) *Aspergillus nidulans* and chronic granulomatous disease: a unique host-pathogen interaction. *J Infect Dis* 206:1128–1137
42. Bondioni MP, Lougaris V, Di Gaetano G et al (2017) Early identification of lung fungal infections in chronic granulomatous disease (CGD) using multidetector computer tomography. *J Clin Immunol* 37:36–41
43. Magnani A, Brosselin P, Beauté J et al (2014) Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease. *J Allergy Clin Immunol* 134:655–662

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.